.Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio-
Morbid Obesity
Poitiers University HospitalSmall moleculePhase 2/3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 81/ 100
Competitive context
61 Active assets in the Morbid Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lidocaine Instituto Mexicano del Seguro Social | Phase 4 | BBB |
Colesevelam Hvidovre University Hospital | Phase 4 | BBB |
Propofol G.Gennimatas General Hospital | Phase 4 | BBB |
Ramifentanyl Hospital dos Lusíadas | Phase 4 | BBB |
Chenodeoxycholic Acid Hvidovre University Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
.Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →